Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International prospective trial in high-risk medulloblastoma patients older than 3 years
2018-004250-17Phase 3Unknown
- Sponsor
- University of Birmingham
- Start
- Dec 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of thiotepa, vincristine, lomustine, cyclophosphamide, temozolomide and 2 more in medulloblastoma (3 arms), sponsored by University of Birmingham. Primary endpoint: Event-free survival. Status: unknown.
02
Drugs
thiotepavincristinelomustinecyclophosphamidetemozolomide
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on 2018-004250-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004250-17.